Effects of betamethasone on maternal plasma corticotropin releasing factor, ACTH and cortisol during pregnancy.
Corticotropin releasing factor immunoactivity (CRFi) has been identified in the plasma of women in the second half of gestation. There are several lines of evidence supporting a placental source for this hormone. Regulation of placental CRFi is poorly understood. In this study, the effect of a long-acting glucorticoid on the release of placental CRFi was investigated. Eleven women in the third trimester of pregnancy had plasma samples measured for CRFi, ACTH and cortisol before and after receiving 12 mg betamethasone. There was a significant decrease in ACTH (p less than 0.05) and cortisol levels (p less than 0.01) but no change in CRFi. It is concluded that the secretion of CRFi by the placenta is not inhibited by the administration of betamethasone while maternal levels of cortisol and ACTH are lowered. These results suggest that the acute regulation of placental CRFi is distinct from the regulation of hypothalamic CRF.
Tropper
P J
PJ
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York.
Goland
R S
RS
Wardlaw
S L
SL
Fox
H E
HE
Frantz
A G
AG
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D001623:Betamethasone / Q000494:pharmacology*; D003346:Corticotropin-Releasing Hormone / Q000097:blood* / Q000276:immunology / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D011247:Pregnancy / Q000097:blood*; D011263:Pregnancy Trimester, Third
D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D001623:Betamethasone; D006854:Hydrocortisone